专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

KR1020000049546A 키토산 함유 구강청정제 및 그 제조방법 无效
标题翻译：含有谷氨酸盐的洗涤剂及其制备方法
公开(公告)号：KR1020000049546A
公开(公告)日：2000-08-05
申请号：KR1020000018318
申请日：2000-04-07
申请人： 주식회사 오스코텍 , 이현주 , 권오규 , 정동식 , 이성철 , 고선일 , 임성빈 , 유영목 , 신동령 , 김형건 , 김종여 , 김정근 , 김세원 , 임창준 , 한국유나이티드제약 주식회사
发明人： 김정근 , 길영식 , 안승호 , 신현종 , 배건우 , 조재민
IPC分类号： A61K8/98 , A61K8/73 , A61Q11/00
摘要： PURPOSE: A novel mouth wash composition comprises specific molecular weight of aqueous chitosan instead of chemical antibiotic agents in the conventional mouth wash. The novel mouth wash has an improved efficacy and stability and improves oral hygiene. CONSTITUTION: A novel mouth wash is characterized by adding 0.01-1% of chitosan having 3,000-13,000 Da of molecular weight to a surfactant, a stabilizing agent, a sweetening agent, a flavoring agent, a colorant and a solvent. A preparation method of the mouth wash is characterized by the following steps of: obtaining albumen only from eggs and then diluting the albumen with distilled water; adding the diluted albumen to chitosan solution; homogenizing by warming up in a double boiler at 90°C for 30 minutes; centrifuging at 12,000 rpm for 10 minutes followed by collecting supernatant; and adding the supernatant to the conventional mouth wash comprising the components mentioned above. The multi-functional mouth wash has not only an antibiotic activity but also protection activity, such as inhibiting noxious effect of organic acid and promoting separation or inhibiting bond of hydroxyaptite and Streptococcus mutans, and treatment activity such as promoting reforming of oral soft tissue and osteoconduction.
摘要翻译：目的：新型漱口水组合物包含特定分子量的水性壳聚糖代替常规漱口水中的化学抗生素。新颖的漱口水具有改进的功效和稳定性并改善口腔卫生。构成：新型漱口水的特征在于向表面活性剂，稳定剂，甜味剂，调味剂，着色剂和溶剂中加入0.01-1％具有3,000-13,000Da分子量的壳聚糖。漱口水的制备方法的特征在于以下步骤：仅从鸡蛋中获得白蛋白，然后用蒸馏水稀释白蛋白; 将稀释的蛋白加入壳聚糖溶液中; 通过在双层锅炉中在90℃下预热30分钟来均化; 以12,000rpm离心10分钟，然后收集上清液; 并将上清液加入到包含上述组分的常规漱口水中。多功能漱口水不仅具有抗菌活性，而且具有抑制有机酸的有害作用，促进羟基磷酸酯和变形链球菌分离抑制作用等保护作用，促进口腔软组织改造和骨传导等治疗活性。

2. 发明授权

KR100477376B1 멜록시캄의 가용화 조성물 및 그의 제조방법 失效
标题翻译：美洛昔康的溶解及其制备方法
公开(公告)号：KR100477376B1
公开(公告)日：2005-03-18
申请号：KR1020020035945
申请日：2002-06-26
申请人： 한국유나이티드제약 주식회사
发明人： 다한이멜다 , 신현종
IPC分类号： A61K31/541
摘要： 1) L-글리신, L-알라닌 또는 L-발린 중에서 선택한 1종의 수용성 아미노산 1.0 ∼ 30 중량%을 에탄올 10 ∼ 50 중량%, 프로필렌글리콜 50 ∼ 80 중량% 및 정제수에 용해한 후, 여기에 디에탄올아민 3.0 ∼ 10 중량% 와 멜록시캄을 추가하여 용해시키고 일야 방치 후 휘발시켜 제조된 멜록시캄 가용화 복합체액 1.0 ∼ 40 중량% 와, 2) 미결정 셀룰로오스, 메칠셀룰로오스, 히드록시프로필메칠셀룰로오스, 히드록시프로필셀룰로오스 또는 카르복시메칠셀룰로오스 나트륨 중에서 선택한 1종이상의 분말결합제 10 ∼ 30 중량%, 3) 유당, 직타유당, 호화된전분, 만니톨, 소르비톨 또는 인산칼슘 중에서 선택한 1종이상의 부형제 10 ∼ 80 중량%, 4) 스테아린산마그네슘, 탈크, 스테아린산, 경질이산화규소 중에서 선택한 1종이상의 활택제 0.1 ∼ 10 중량% 및 5) 크로스포비돈, 건조옥수 수전분, 소디움스타치글리코네이트, L-HPC, 가교 결합된 카르복시메칠셀룰로오스 칼슘 중에서 선택한 1종이상의 붕해제 0.5 ∼ 10 중량%로 구성된 멜로시캄 함유 경구용 제제에 관한 것으로, 용출률 개선의 특장점이 있다.

3. 发明公开

KR1020040106915A 가용성 이부프로펜의 연질캅셀제 조성물 및 그의 제조방법 无效
标题翻译：溶解IBUPROFEN软胶囊的组合物及其制备方法，其通过溶解聚乙烯醇，聚乙烯吡咯烷酮，聚氧乙烯醚，二乙醇胺和碱性氨基酸的混合溶液中的IBUPROFEN
公开(公告)号：KR1020040106915A
公开(公告)日：2004-12-20
申请号：KR1020030036187
申请日：2003-06-05
申请人： 한국유나이티드제약 주식회사
发明人： 유창훈 , 길영식 , 홍석천 , 양근우 , 정기훈 , 안건석 , 신현종
IPC分类号： A61K9/48
CPC分类号： A61K9/4858 , A61K9/4866 , A61K31/192 , A61K47/10 , A61K47/38
摘要： PURPOSE: Provided is a composition of the solubilized ibuprofen soft capsule and a manufacturing process thereof, thereby increasing dissolution rate of ibuprofen and absorption thereof into the human body. CONSTITUTION: The method for manufacturing the composition of the solubilized ibuprofen soft capsule is characterized by dissolving ibuprofen or the mixture of ibuprofen and water soluble polymeric compound in the hydrophilic solubilizing agent, and adding at least one or two kinds of surfactant, diethanolamine or basic amino acid thereto to dissolve the ibuprofen.
摘要翻译：目的：提供可溶性布洛芬软胶囊的组合物及其制造方法，由此增加布洛芬的溶出速度及其对人体的吸收。构成：可溶性布洛芬软胶囊的组合物的制造方法的特征在于将布洛芬或布洛芬和水溶性高分子化合物的混合物溶解在亲水性增溶剂中，并加入至少一种或两种表面活性剂，二乙醇胺或碱性氨基酸化以溶解布洛芬。

4. 发明授权

KR100446829B1 가용화된 피록시캄을 함유한 확산형 정제의 조성물 및그의 제조방법 失效
标题翻译： 가용화된록시캄을함유한확산형정제의조성물및그의제조방
公开(公告)号：KR100446829B1
公开(公告)日：2004-09-04
申请号：KR1020020008971
申请日：2002-02-20
申请人： 한국유나이티드제약 주식회사
发明人： 단이멜다 , 홍석천 , 유창훈 , 길영식 , 신현종
IPC分类号： A61K9/20
摘要： PURPOSE: Provided are a dispersible tablet containing solubilized piroxicam and a manufacturing method thereof. The manufactured dispersible tablet is easily eluted and absorbed and has excellent pharmacological activity. CONSTITUTION: A dispersible tablet is manufactured by dissolving 0.1-3 wt.% of L-arginine in 1-5 wt% of purified water containing ethanol; adding 0.1-30 wt.% of diethanolamine and 0.1-50 wt.% of piroxicam to the dissolution and dissolving them to give a mixed solution of piroxicam and L-arginine; and adding 1.0-60 wt.% of excipient, 1.0-30 wt.% of powder binding agent, 1.0-20 wt.% of a sweetener, 0.1-5.0 wt.% of lubricant, 0.5-25 wt.% of disintergrant to 1.0-20 wt.% of the mixed solution.
摘要翻译：用途：提供一种含有溶解吡罗昔康的分散片及其制造方法。制得的分散片容易洗脱和吸收，具有优异的药理活性。构成：分散片通过将0.1-3重量％的L-精氨酸溶解在1-5重量％的含乙醇的纯化水中制得; 加入0.1-30重量％二乙醇胺和0.1-50重量％吡罗昔康溶解并溶解，得到吡罗昔康和L-精氨酸的混合溶液; 并添加1.0-60重量％的赋形剂，1.0-30重量％的粉末粘合剂，1.0-20重量％的甜味剂，0.1-5.0重量％的润滑剂，0.5-25重量％的崩解剂，混合溶液的1.0-20重量％。

5. 发明公开

KR1020030085861A 카르바마제핀 서방정 조성물과 그의 제조방법 有权
标题翻译：含有卡巴胺的持续释放片组合物及其制备方法
公开(公告)号：KR1020030085861A
公开(公告)日：2003-11-07
申请号：KR1020020024146
申请日：2002-05-02
申请人： 한국유나이티드제약 주식회사
发明人： 유창훈 , 홍석천 , 길영식 , 신현종
IPC分类号： A61K9/22
CPC分类号： A61K9/2027 , A61K9/2009 , A61K9/2013 , A61K9/2054 , A61K31/55
摘要： PURPOSE: Provided is a sustained release tablet composition containing carbamazepine as an active ingredient and a polymer carrier permeable to water but slightly soluble in water as a sustained release substrate. It shows the dissolution rate of 80% or less 8 hours after administration. CONSTITUTION: A sustained release tablet composition contains 70 to 80% by weight of carbamazepine as an active ingredient, 5 to 20% by weight of a buffer, calcium phosphate dibasic as a stabilizer, 0.5 to 10% by weight of Eudragit RS-100 as a sustained release substrate, 0.5 to 10% by weight of povidone as a binding agent, 0.5 to 5.0% by weight of calcium carboxymethyl cellulose and 0.5 to 5.0% by weight of microcrystalline cellulose as a disintegrating agent, 0.5 to 5.0% by weight of talc and 0.5 to 5.0% by weight of magnesium stearate as lubricating agent. The initial daily dose of the tablet is 200 to 400mg, based on adults.
摘要翻译：目的：提供含有卡马西平作为活性成分的缓释片剂组合物和可渗透水但微溶于水作为缓释底物的聚合物载体。表明给药后8小时的溶出率为80％以下。构成：持续释放片剂组合物含有70〜80重量％的作为活性成分的卡马西平，5〜20重量％缓冲液，磷酸氢二钙作为稳定剂，0.5〜10重量％的Eudragit RS-100作为缓释底物，0.5〜10重量％的作为粘合剂的聚维酮，0.5〜5.0重量％的羧甲基纤维素钙和0.5〜5.0重量％的微晶纤维素作为崩解剂，0.5〜5.0重量％滑石和0.5-5.0重量％的硬脂酸镁作为润滑剂。片剂的初始日剂量为200至400mg，基于成人。

6. 发明公开

KR1020030056474A 카르비도파/레보도파 서방정의 조성물과 그의 제조방법 无效
标题翻译： LEVODOPA / CARBIDOPA的持续释放片组合物及其生产
公开(公告)号：KR1020030056474A
公开(公告)日：2003-07-04
申请号：KR1020010086690
申请日：2001-12-28
申请人： 한국유나이티드제약 주식회사
发明人： 신현종 , 유창훈
IPC分类号： A61K9/24
CPC分类号： A61K9/2027 , A61K9/2018 , A61K9/2054 , A61K31/121 , A61K31/198
摘要： PURPOSE: A new sustained release tablet composition as a matrix type or single drug administration system containing carbidopa and levodopa as an active component is provided. The sustained release tablet composition exhibits an elution rate of about 60% within 1 hour and 90% or more within 2 hour after administration. Therefore, it uniformly and slowly releases an active ingredient. CONSTITUTION: Carbidopa and levodopa are blended with 0.5 to 5% by weight of Eudragit RL-30D or Eudragit RL-100 and the mixture is added with purified water, dried at 50deg.C in a fluidized bed drier for 30min, mixed with a lubricating agent and tabletted. For an example, 16.7% by weight of carbidopa(anhydride) USP is blended with levodopa KP, 13.0% by weight of lactose, 1.6% by weight of Eudragit RL-30D, 1.0% by weight of talc and 1.0% by weight of magnesium stearate and dried at 50deg.C for 30min.
摘要翻译：目的：提供一种新的持续释放片剂组合物作为含有卡比多巴和左旋多巴作为活性成分的基质或单一药物给药系统。持续释放片剂组合物在给药后2小时内在1小时内显示出约60％的洗脱速率和90％以上的洗脱速率。因此，它均匀缓慢释放活性成分。构成：将卡比多巴和左旋多巴与0.5〜5重量％的Eudragit RL-30D或Eudragit RL-100混合，加入纯化水，在流化床干燥器中在50℃下干燥30分钟，与润滑剂代理和压片。例如，将16.7重量％的卡比多巴（酸酐）USP与左旋多巴KP，13.0重量％乳糖，1.6重量％Eudragit RL-30D，1.0重量％滑石和1.0重量％镁硬脂酸酯并在50℃下干燥30分钟。

7. 发明公开

KR1020030021853A 가용화된 펠로디핀 함유 지속성제제의 조성물 및 그의제조방법 有权
标题翻译：含有可溶性菲咯地平及其生产的持续释放配方
公开(公告)号：KR1020030021853A
公开(公告)日：2003-03-15
申请号：KR1020010055305
申请日：2001-09-08
申请人： 한국유나이티드제약 주식회사
发明人： 신현종 , 길영식
IPC分类号： A61K9/22
CPC分类号： A61K9/2013 , A61K9/1676 , A61K9/2009 , A61K31/4422 , A61K47/12 , A61K47/32
摘要： PURPOSE: A method for producing the titled formulation by solubilizing felodipine as a drug sparingly soluble in water in methylene chloride and ethanol and then spray drying is provided. Whereby, the formulation permits sustained release of a drug for a specified time to increase a therapeutic effect. CONSTITUTION: An effective amount of felodipine is solubilized with 0.5 to 20% by weight of polyvinylpyrrolidone as a water soluble polymer compound in a mixed solvent of methylene chloride and ethanol and then spray dried to produce solid dispersants. Thereafter, the dispersants are mixed with a sustained release base comprising 40 to 70% by weight of lactose, 5 to 40% by weight of Eudragit, 10 to 30% by weight of dicalcium phosphate dihydrate, 0.1 to 3% by weight of a lubricating agent and 0.1 to 3% by weight of magnesium stearate.
摘要翻译：目的：通过将非洛地平作为在二氯甲烷和乙醇中微溶于水的药物溶解，然后喷雾干燥来制备标题制剂的方法。因此，该制剂允许持续释放药物达指定时间以增加治疗效果。构成：在二氯甲烷和乙醇的混合溶剂中，将有效量的非洛地平与0.5〜20重量％的作为水溶性高分子化合物的聚乙烯吡咯烷酮溶解后，喷雾干燥，生成固体分散剂。此后，将分散剂与包含40-70重量％乳糖，5-40重量％Eudragit，10-30重量％磷酸二钙二水合物，0.1-3重量％润滑剂试剂和0.1〜3重量％的硬脂酸镁。

8. 发明公开

KR1020000072647A 세파클로르 서방정의 조성물 및 그의 제조방법 有权
标题翻译： CEPHACHLOR持续释放片组合物和制备方法
公开(公告)号：KR1020000072647A
公开(公告)日：2000-12-05
申请号：KR1020000054567
申请日：2000-09-18
申请人： 한국유나이티드제약 주식회사
发明人： 신현종
IPC分类号： A61K9/22
CPC分类号： A61K9/28 , A61K9/1652 , A61K9/5015 , A61K31/545
摘要： PURPOSE: Provided is cephachlor sustained-release tablet compositions for providing continuously a medical action by making a persistent granule containing a speedily soluble granule in a tablet and a preparation method thereof is provided. CONSTITUTION: A cephachlor sustained-release tablet composition comprises about 30 to 95 wt.% of cephachlor, 1 to 3 wt.% of water-soluble binder, 0.1 to 30 wt.% preferentially, 1 to 10 wt.% of sustained matrix substrate, and 0.1 to 14 wt.% of lubricant. The composition is characterized in that a speedily-solubled granule is released at early stage and persistent granule is released at the late stage, thereby, active ingredients are released at regular intervals through stomach and intestines. The releasing speed is controlled by the kind and the content of a binder at the early stage then by the content of a lubricant at the late stage.
摘要翻译：目的：提供通过在片剂中制备含有快速溶解颗粒的持久性颗粒而连续提供医疗作用的头孢菌素缓释片剂组合物及其制备方法。构成：含有约30〜95重量％的乙草胺，1〜3重量％的水溶性粘合剂，0.1〜30重量％，优选1〜10重量％的持续基质底物，和0.1〜14重量％的润滑剂。该组合物的特征在于，早期释放快速溶解的颗粒，并且在晚期释放持续性颗粒，由此通过胃和肠以有规律的间隔释放活性成分。释放速度由早期阶段的粘合剂的种类和含量由后期的润滑剂含量控制。

9. 发明公开

KR1019990083714A 아시클로버 확산정의 조성물 및 그의 제조방법 有权
标题翻译：阿昔洛韦片剂的分散制剂及其制备方法
公开(公告)号：KR1019990083714A
公开(公告)日：1999-12-06
申请号：KR1019990023425
申请日：1999-06-22
申请人： 한국유나이티드제약 주식회사
发明人： 신현종
IPC分类号： A61K31/52
摘要： 본발명은, 아시클로버 25∼95 중량%, 붕해제 0.5∼25 중량%, 유기산 1∼30 중량%와탄산염 1∼30 중량%로구성된확산제, 감미제 0.1∼5 중량%, 부형제 5∼30중량%, 착향제, 분말결합제 1∼30 중량% 및활택제 0.2∼2.5 중량%로구성된아시클로버함유확산정조성물및 그제조방법에관한것으로, 붕해가신속하고, 복용하기가편리하며, 구강내에서도물없이붕해되어간편하게투여할수 있다는특장점이있다.

10. 发明公开

KR1020040045238A 이트라코나졸의 용해도 개선을 위한 펠렛제제 및 그제조방법 有权
标题翻译：改善异烟肼溶解性的颗粒配方及其制造方法
公开(公告)号：KR1020040045238A
公开(公告)日：2004-06-01
申请号：KR1020020073300
申请日：2002-11-23
申请人： 한국유나이티드제약 주식회사
发明人： 길영식 , 조동현 , 홍석천 , 유창훈 , 신현종
IPC分类号： A61K9/20
CPC分类号： A61K9/1676 , A61K31/496 , A61K47/12 , A61K47/36
摘要： PURPOSE: Provided are a pellet formulation for improving the solubility of itraconazole having increased bioavailability and a method for manufacturing the same effectively, thereby improving the stability, solubility and treatment of itraconazole. CONSTITUTION: A method for manufacturing a pellet formulation for improving solubility of itraconazole is characterized by the steps of: dissolving itraconazole, and hydrophilic polymer, organic acid or amino acid in a co-solvent; spray-drying the dissolution to give uniform spray-dried products; and spraying the spray-dried products to inactive spherical granules to give pellet formulations having a size of 100-1500 μm.
摘要翻译：目的：提供用于提高具有增加的生物利用度的伊曲康唑的溶解度的丸剂制剂及其制备方法，从而提高伊曲康唑的稳定性，溶解度和治疗效果。构成：制备用于改善伊曲康唑溶解度的丸剂制剂的方法的特征在于以下步骤：将伊曲康唑和亲水性聚合物，有机酸或氨基酸溶解在共溶剂中; 喷雾干燥溶解，得到均匀的喷雾干燥产品; 并将喷雾干燥的产品喷洒到无活性的球形颗粒上，得到尺寸为100-1500μm的颗粒制剂。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式